absorb.md

Bill Gurley

Chronological feed of everything captured from Bill Gurley.

podcast_episode / 1d ago

BG2Pod with Brad Gerstner and Bill Gurley: AI Bubble, Stablecoin Boom, and Runnin' Down a Dream | BG2 w/ Bill Gurley and Brad Gerstner

<p>Pre-Order Runnin' Down a Dream now: https://a.co/d/0oIPPve</p><p>Open Source bi-weekly convo w/ Bill Gurley and Brad Gerstner on all things tech, markets, investing & capitalism. This week, they unpack the $3T AI buildout, circular revenue red flags, and whether the boom is becoming a bubble. They dive into the rise of stablecoins and the new financial rails reshaping money, the fight over AI regulation in America, and Bill’s next chapter—his new book Runnin' Down a Dream and what it means to build a career you actually love. Enjoy another episode of BG2!</p><p...

podcast_episode / 1d ago

Afford Anything | Make Smart Money Choices: Bill Gurley: The Biggest Career Regret Most People Have

<p>#697: Most people regret the things they never tried.</p> <p>Venture capitalist Bill Gurley says that pattern shows up again and again in research on end-of-life regrets — including regret about the careers people never pursued. </p> <p>In this episode, Gurley joins us to talk about how people actually discover work they enjoy - and why the cliché to “follow your passion” sends people in the wrong direction.</p> <p>We start with a question many listeners wrestle with: what if you reach your forties or fifties and still do not know what you want to do? </p> <p>Gurley ex...

podcast_episode / 1d ago

Leap Academy with Ilana Golan: Benchmark Partner, Bill Gurley: The Strategy That Makes You Stand Out in a Crowded Job Market | E150

<p>When Bill Gurley wanted to break into Wall Street, there were no job postings waiting for him. So he flew to New York, knocked on doors, and asked strangers for meetings. That hustle launched a career that would eventually take him to Silicon Valley, where he became one of the most respected venture capitalists in tech. In this episode, Bill joins Ilana to reveal the unconventional lessons that shaped his journey. From chasing curiosity to designing your own career path, he explains how anyone can create opportunities, stand out in a crowded field, and build a career that actually...

podcast_episode / 1d ago

Impossible Dreams: Bill Gurley: Running Down a Dream | Episode 23

<p>What if the key to career success isn't following the safe path—but chasing the thing that gives you energy instead of draining it? </p><p>In this inspiring episode, host Aaron Lazar sits down with Bill Gurley—legendary venture capitalist, General Partner at Benchmark, early investor in Uber, Zillow, and OpenTable, and New York Times bestselling author of Runnin' Down a Dream: How to Thrive in a Career You Actually Love. From his days as a college basketball player at the University of Florida to leading the Amazon IPO as a Wall Street analyst to backing some of the...

tweet / 1d ago

"So You Want to be a VC" Im enjoying this week in Boston visiting students promoting my new book - Runnin Down a Dream. Not surprisingly, many ask me about trying to break into venture capital. I wro

"So You Want to be a VC" Im enjoying this week in Boston visiting students promoting my new book - Runnin Down a Dream. Not surprisingly, many ask me about trying to break into venture capital. I wrote a letter answering this question 15 years ago. I would send it out when people inquired. I'm making it public for the first time - with zero modifications. 1) I think it holds up well 2) make sure and read my new book also 3) I probably can't help with followups (as suggested in the letter) Hope you find it useful. Good luck!

paper / 1d ago

An exploratory evaluation of the interaction risk between herbal products and pharmaceutical medicines used concurrently for disease management in Blantyre, Malawi

Abstract Context The use of herbal products in Malawi remains widespread and culturally significant, often occurring alongside pharmaceutical medicine treatments. As the burden of non-communicable diseases such as diabetes and hypertension continues to rise, the potential for herbal-drug interactions (HDIs) represents an underexamined public health concern. Objective Evaluate the concurrent use of herbal products and pharmaceutical medicines among patients with diabetes or hypertension in a large health care facility in Malawi and identify potential adverse HDIs. Materials & Methods An exploratory mixed-methods, cross-sectional study was conducted with 301 patients attending a diabetes or hypertension clinic at Queen Elizabeth Central Hospital in Blantyre, Malawi. Participants self-reported herbal and pharmaceutical use, and a targeted literature review was undertaken to assess potential pharmacokinetic and pharmacodynamic interactions between commonly reported herbal products and prescribed medications. Results Participants reported concurrent use of a wide variety of herbal products (e.g., garlic, ginger, okra, lemon, mango, moringa) with prescription medicines (e.g., metformin, insulin, glibenclamide, hydrochlorothiazide, enalapril, amlodipine). While clinical outcomes were not independently verified, literature review findings, in some cases, indicated meaningful potential for HDIs. Discussion and Conclusion This study provides foundational data on herbal-pharmaceutical co-use in Malawi and highlights the need for expanded research, improved documentation of herbal use in healthcare settings, and improved education for patients and providers. Integrating awareness of herbal product use into clinical care is essential, and the methodology and findings may inform future hypothesis-driven studies across Africa and other regions where traditional and modern medicine use overlaps.

paper / 1d ago

From Vision to Reality: Five Years of the Botanical Safety Consortium

Abstract Context Botanicals, including products derived from plants, fungi, and algae, are increasingly consumed worldwide. Their complex compositions and variable phytochemical profiles present significant challenges for safety assessment. Traditional toxicology methods are time and resource intensive, and the variability of botanicals makes it difficult to test one lot as representative. Objective The Botanical Safety Consortium (BSC), launched in 2019, was established to advance fit-for-purpose toxicity testing strategies for botanicals. This manuscript summarizes the progress of the BSC, with emphasis on the activities of its Working Groups. Methods The BSC Working Groups evaluate established new approach methodologies (NAMs), including in vitro assays, in silico models, and non-protected whole organisms such as C. elegans, for their applicability to botanical hazard assessment. Case studies of botanicals were selected based on known toxicity profiles to test assay performance and determine whether botanicals behave differently from single chemicals in these systems. Results The evaluations address toxicological endpoints such as hepatotoxicity, genotoxicity, developmental and reproductive toxicity, neurotoxicity, cardiotoxicity, and dermal toxicity. Early findings have identified fit-for-purpose screening tools that can generally be applied to botanical testing, with some nuances and considerations. Conclusion Future work will focus on refining and enhancing the tool-kit through assay refinement, filling endpoint gaps with additional assays, and incorporating ADME data and in silico modeling approaches. This collaborative, science-driven framework aims to modernize botanical safety evaluation, address regulatory needs, and ultimately protect public health while supporting the global demand for botanical-based dietary supplements, cosmetics, and other products.

paper / 1d ago

Formulation-dependent dissolution and bioaccessibility of curcuminoids and (S)-ar-turmerone from eight commercial turmeric extract- and curcumin-containing dietary supplements.

CONTEXT Curcumin-containing dietary supplements are widely marketed with claims of enhanced bioavailability, despite well-recognized limitations related to poor aqueous solubility, chemical instability, and extensive first-pass metabolism. Comparisons among commercially available products using physiologically relevant performance metrics remain limited. OBJECTIVE To systematically evaluate disintegration, dissolution, and bioaccessibility of curcuminoids and (S)-ar-turmerone from a cross section of commercially available turmeric dietary supplements under fasted- and fed-state biorelevant conditions. MATERIALS AND METHODS Eight marketed turmeric supplements representing diverse formulation strategies were assessed for disintegration and dissolution using USP-aligned methods in fasted- and fed-state simulated gastric and intestinal media (FaSSGF, FaSSIF, FeSSGF, FeSSIF). Bioaccessible concentrations, quantities, and dose fractions of curcuminoids and (S)-ar-turmerone were quantified after 3 h. RESULTS All products exhibited poor dissolution overall, with no formulation achieving greater than 40% total release. Dissolution was lowest under fasted-state conditions and improved modestly in fed-state gastric media, reflecting the influence of lipid content. Products with higher curcuminoid loads per capsule generated greater absolute bioaccessible concentrations despite poor release efficiency, whereas a phytosome formulation achieved superior release despite a lower dose. Several products marketed as "enhanced" formulations demonstrated poor disintegration and low bioaccessibility. DISCUSSION These findings indicate that bioaccessible concentration is governed jointly by dosage-form performance and curcuminoid dose loading, and that plasma exposure metrics dominated by conjugated metabolites may not reliably reflect formulation performance. CONCLUSION Commercial turmeric supplements exhibit substantial limitations in biorelevant disintegration and dissolution. Superior in vitro release is a prerequisite - but not a guarantee - for enhanced systemic exposure, underscoring the need for cautious interpretation of bioavailability claims.